Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RYZ801 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RYZ811 | DIAGNOSTIC_TEST | Ga-68 |
| RYZ801 | DRUG | Ac-225 |
RYZ801 is an investigational small molecule therapeutic being developed by Bristol-Myers Squibb Company (ticker: BMY) for hepatocellular carcinoma (HCC), a form of liver cancer. It is in Phase 1 clinical development and is designed for use as part of a theranostic pair alongside a diagnostic agent, RYZ811.
RYZ801 is being studied for the treatment of GPC3-positive unresectable hepatocellular carcinoma (HCC). It is intended for use with the diagnostic agent RYZ811, which identifies patients whose tumors express GPC3 so that the therapeutic can then be given to that biomarker-selected population.
RYZ801 targets BCMA, a protein. It is a small molecule therapeutic, and the clinical program pairs it with the diagnostic agent RYZ811 to identify and treat subjects with GPC3-positive unresectable hepatocellular carcinoma.
RYZ801 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is running the Phase 1 study of the therapeutic as part of a theranostic pair with the diagnostic agent RYZ811 in GPC3-positive unresectable hepatocellular carcinoma.
RYZ801 is in Phase 1 clinical development. It is an investigational agent and has not been approved for any indication. The Phase 1 program is currently recruiting participants and is designed to evaluate the therapeutic in a biomarker-selected population of patients with GPC3-positive unresectable hepatocellular carcinoma.
RYZ801 is being studied in one active clinical trial, NCT06726161, titled "Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC." The trial is a Phase 1, recruiting, uncontrolled study with a planned enrollment of 70 participants.